Breast cancer and other aggressive cancers may respond to anti-inflammatory drugs
 

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis.

More...

Re: Breast cancer and other aggressive cancers may respond to anti-inflammatory drugs
 

JAK stands for Janus Kinase. The anti-arthritic drug they are referring to is Tofacitinib brand name Xeljanz. The dosage is 5mg twice a day. When I read the Xeljanz information it seemed at least theoretically it could have anti-cancer action.

There is another FDA inhibitor of the Janus kinases called Jakafi generic name Ruxolotinib. It is given in a dosage of 20mg two times daily for Myelofibrosis.

Paul